Clinical Trial

Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study will test a study drug called cemiplimab to see if it can help treat early-stage Cutaneous Squamous Cell Carcinoma (CSCC), a type of skin cancer. Cemiplimab works by helping the immune system to kill cancer cells. It binds to a protein called Programmed cell Death-1 (PD-1) on the surface of certain immune cells. The main purpose of this study is to compare how well cemiplimab works compared to surgery, when injected into the lesion. The study is looking at: * The side effects cemiplimab might cause * How well cemiplimab works compared to surgery
Protocol Amendment History 23 amendments
This ClinicalTrials.gov record has been amended 23 times since 2024-09-03; most recent amendment 2026-07-07.
Status change: Not Yet Recruiting → Recruiting 2025-01-17
Trial Details
NCT Number NCT06585410
Lead Sponsor Regeneron Pharmaceuticals
Conditions Cutaneous Squamous Cell Carcinoma (CSCC)
Enrollment 369 participants
Start Date 2025-01-02
Primary Completion 2030-05-03 (estimated)
Study Completion 2030-05-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-08